UK to offer meningitis B vaccines to teenagers after fatal outbreaks
UK government advisers have recommended routine meningitis B vaccinations for all teenagers, a major public health policy shift prompted by recent fatal outbreaks that overwhelmed local health services.
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government to offer the meningitis B vaccine to all teenagers. This would expand state-backed protection against a deadly infection.
The recommendation follows severe outbreaks that disrupted public life. In March, an "unprecedented" cluster in Kent linked to a nightclub killed two people, including 18-year-old Juliette Kenny, and experts described it as the quickest-growing spread they had ever seen. A separate outbreak in Berkshire in May killed a school student.
For the UK's publicly funded health system, the JCVI's advice represents a substantial new logistical and financial commitment. As an immediate precaution, the NHS is already executing a one-off campaign this summer to vaccinate roughly a million young people before they enter university or other residential education settings this autumn.
Under the committee's long-term plan, teenagers would receive a booster dose at age 15 if they were immunised as infants, with the first eligible cohort turning 15 in 2030. Children born on or before April 30, 2015, who missed the infant programme entirely, would be offered two doses at age 15 to close the immunity gap.
Meningitis B is the most common bacterial form of meningococcal disease, an infection of the protective lining of the brain and spinal cord. England typically records 300 to 400 cases annually. While large outbreaks are rare, the sudden healthcare costs and loss of life demonstrate the economic and social risks of leaving older teenagers unprotected.
Prof Wei Shen Lim, the JCVI chair, highlighted that the committee had worked closely with charities and considered the experiences of those affected. “Invasive meningococcal disease is a rare but very serious illness, which can have a devastating impact on lives,” he said.
Dr Tom Nutt, chief executive of Meningitis Now, described the recommendation as a “significant moment in the fight against meningitis”. He noted that young people remain at increased risk, and praised the families who had channelled their grief into campaigning for wider vaccine access.
